GlassScriptPhysician profile
Taylor J Hess
NPI 1154811685
$69,562.87
in general payments reported to CMS, 2019-2025
30 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $233 · 2021: $376 · 2022: $306 · 2023: $26K · 2024: $17K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Consulting Fee: $17K · Honoraria: $9,000 · Food and Beverage: $7,188 · Travel and Lodging: $2,214 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,790.00 |
| Consulting Fee | $16,789.00 |
| Honoraria | $9,000.00 |
| Food and Beverage | $7,187.66 |
| Travel and Lodging | $2,213.77 |
| Education | $173.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $22,359.90 | 2022-2025 | Vumerity, Tysabri |
| Genzyme Corporation | $14,923.14 | 2019-2025 | |
| Horizon Therapeutics Plc | $11,090.29 | 2022-2023 | Uplizna |
| Emd Serono, INC. | $8,819.88 | 2022-2025 | Mavenclad |
| Genentech USA, INC. | $5,279.63 | 2019-2024 | Ocrevus, Enspryng |
| Amgen INC. | $3,000.92 | 2024-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $1,237.07 | 2023-2025 | |
| Tg Therapeutics, INC. | $1,094.54 | 2023-2025 | |
| Abbvie INC. | $381.01 | 2023-2024 | |
| Ucb, INC. | $191.75 | 2020-2024 | Briviact, Rystiggo |
| Alexion Pharmaceuticals, INC. | $153.09 | 2019-2024 | |
| Greenwich Biosciences, INC. | $126.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $110.27 | 2021 | |
| Sk Life Science, INC. | $108.09 | 2020 | |
| Lilly USA, LLC | $95.54 | 2023-2024 | Emgality, Amyvid, Kisunla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $94.38 | 2023-2024 | Ingrezza |
| Pfizer INC. | $72.63 | 2023-2024 | |
| Celgene Corporation | $70.44 | 2023-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $51.20 | 2024 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $49.32 | 2023-2024 | Austedo Xr, Austedo |
| Argenx US, INC. | $46.19 | 2023-2024 | Vyvgart |
| Harmony Biosciences LLC | $43.54 | 2024 | |
| Lundbeck LLC | $25.50 | 2024 | Vyepti |
| Neurelis, INC. | $24.13 | 2022 | |
| Eisai INC. | $24.08 | 2024 | |
| Allergan, INC. | $21.70 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.55 | 2024 | Keveyis |
| Boston Scientific Corporation | $19.39 | 2025 | Wavewriter Alpha Prime 16 |
| Sanofi-Aventis U.S. LLC | $14.82 | 2021 | |
| Acadia Pharmaceuticals INC | $14.72 | 2024 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.